Table 2.
Laboratory markers of hydroxyurea adherence in relation to patients’ age and chronic pain status.
| All participants (N = 113) | |||||||
|---|---|---|---|---|---|---|---|
| Age groups (years) |
Chronic pain |
||||||
| <12 (n = 37) | 12–17 (n = 26) | ≥18 (n = 50) | p Value | Yes (n = 20) | No (n = 93) | p Value | |
| HbF, median (IQR) | |||||||
| Most recent | 8.6 (5.1–20.8) | 12.4 (9.9–16.3) | 24.2 (11.7–30.3) | .003 | 10.7 (4.6-19.5) | 15.3 (8.9-29.3) | .04 |
| Last year | 8.4 (5.1–21.2) | 14 (10.5–20.7) | 24.4 (17.7–24.1) | .001 | 14.5 (4.9-20.7) | 18 (9.8-29.4) | .24 |
| Last 2 years | 10.4 (5.1–15.5) | 16.7 (12.4–24.4) | 21.4 (15.2–26.4) | .01 | 17.4 (8.1-22.5) | 16.1 (10.9-25) | .58 |
| MCV, median (IQR) | |||||||
| Most recent | 95.4 (81.6–102.4) | 96.2 (90.9–113.1) | 106.4 (92.6–116) | .01 | 93.1 (87.9–1003.5) | 102.3 (91.4–112.7) | .1 |
| Last year | 96.4 (85.1–100.4) | 94.6 (92.1–113.4) | 106.2 (95.5–114.6) | .04 | 95.7 (89–112.1) | 99.1 (92–113.4) | .46 |
| Last 2 years | 94.5 (85.7–101.1) | 97.5 (92.3–112.5) | 109.8 (97.3–113.7) | .01 | 96.6 (92.1–109.8) | 100.8 (91.9–112.5) | .29 |
| ANC, median (IQR) | |||||||
| Most recent | 5 (2.9–5.9) | 3.7 (2.7–6.1) | 3.61 (2.3–5.7) | .5 | 6.3 (4–7) | 3.6 (2.3–5.6) | .002 |
| Last year | 4.2 (3.4–6.8) | 4.9 (3.6–6.6) | 3.25 (2.4–4.7) | .01 | 4.2 (3.5–5) | 3.77 (3–5.7) | .66 |
| Last 2 years | 4.4 (3.1–6.7) | 4.8 (3.8–7) | 3.9 (2.8–5.4) | .16 | 4.4 (3.9–6.2) | 4.2 (3.1–6) | .6 |
| Participants with HbSS (N = 99) | |||||||
|---|---|---|---|---|---|---|---|
| Age groups (years) |
Chronic pain |
||||||
| <12 (n = 29) | 12–17 (n = 26) | ≥18 (n = 44) | p Value | Yes (n = 17) | No (n = 72) | p Value | |
| HbF, median (IQR) | |||||||
| Most recent | 9.25 (6.6–26.5) | 12.4 (9.9–16.3) | 24.3 (13.6–33.1) | .01 | 12.8 (8.7–22.6) | 18.4 (9.1–30.3) | .12 |
| Last year | 9.55 (6.45–25.3) | 14 (10.5–20.7) | 24.4 (17.7–32.7) | .001 | 15.9 (9.0–22.8) | 18.8 (10.5–29.4) | .29 |
| Last 2 years | 10.8 (5.3–21.6) | 16.7 (12.4–24.4) | 21.4 (15.2-26.4) | .03 | 17.8 (9.0–24.0) | 16.8 (12.4–25) | .74 |
| MCV, median (IQR) | |||||||
| Most recent | 99.3 (92.5–104.9) | 96.2 (90.9–113.1) | 107.5 (93.6–116.1) | .08 | 96 (91.7–106.6) | 104.1 (93.6–113.1) | .17 |
| Last year | 98.9 (94.9–104.5) | 94.6 (92.1–113.4) | 107 (95.8–114) | .18 | 95.9 (91.1–113.3) | 100 (92.8–114) | .41 |
| Last 2 years | 96.7 (91.3–101.2) | 97.5 (92.3–112.5) | 110.9 (97.3–115.2) | .02 | 96.7 (92.5–110.4) | 101.1 (94.8–113.7) | .28 |
| ANC, median (IQR) | |||||||
| Most recent | 5.1 (2.4–6.4) | 3.7 (2.7–6.1) | 3.5 (2.3–5.7) | .48 | 6.6 (6.9–3.5) | 3.6 (2.3–5.6) | .003 |
| Last year | 4.2 (3.6–6.8) | 4.9 (3.6–6.6) | 3.2 (2.4–4.2) | .002 | 4.1 (3.2–5.9) | 3.7 (3–5.5) | .65 |
| Last 2 years | 4.7 (4.1–7.7) | 4.8 (3.8–7) | 3.7 (2.7–5.2) | .04 | 4.3 (3.8–6.3) | 4.2 (3.1–6.1) | .75 |
p <.05 was statistically significant (highlighted in bold).
ANC: absolute neutrophil count; HbF: foetal haemoglobin; IQR: inter-quartile range; MCV: mean corpuscular volume.